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Abstract 25 
Physiological barriers to drug delivery and selection for drug resistance limit survival outcomes 26 
in cancer patients. In this study, we present preclinical evidence that a subtumoricidal 27 
photodynamic priming (PDP) strategy can relieve drug delivery barriers in the tumor 28 
microenvironment to safely widen the therapeutic window of a nanoformulated cytotoxic drug. 29 
In orthotopic xenograft models of pancreatic cancer, combining PDP with nanoliposomal 30 
irinotecan (nal-IRI) prevented tumor relapse, reduce metastasis and increase both progression-31 
free survival and 1-year disease-free survival. PDP enabled these durable improvements by 32 
targeting multiple tumor compartments to (1) increase intratumoral drug accumulation by >10-33 
fold, (2) increase the duration of drug exposure above a critical therapeutic threshold, and (3) 34 
attenuate surges in CD44 and CXCR4 expression which mediate chemoresistance often observed 35 
after multi-cycle chemotherapy. Overall, our results offer preclinical proof of concept for the 36 
effectiveness of PDP to minimize risks of tumor relapse, progression and drug resistance and to 37 
extend patient survival. 38 
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Introduction 40 
Cancer is a constantly evolving disease that relies on both microenvironmental and 41 
molecular compartments to resist and adapt to therapeutic insults(1). Significant efforts have been 42 
invested in developing chemotherapeutics, biological agents, and cocktails to overcome resistance 43 
mechanisms and escape pathways(2,3). However, these intense multimodal regimens have largely 44 
been hindered by poor drug penetration into solid tumors(4), transient responses that fail to 45 
eradicate aggressive populations with distinct molecular features(5), and significant off-target 46 
toxicities associated with anti-cancer agents(6). 47 
Here, we report a subtumoricidal photochemistry-based approach (hereafter referred to as 48 
Photodynamic Priming, PDP) that primes multiple tumor compartments to enable more potent 49 
and sustained anti-tumor activity of the FDA-approved nanoliposomal irinotecan (nal-IRI, also 50 
known as MM-398, PEP02, BAX2398)(7). This unique photoinitiated approach offers multiple 51 
advantages (Fig.1): (i) At the tumor microenvironmental level, PDP enables spatiotemporally 52 
controlled targeting of physiological barriers to drug delivery for enhanced therapeutic agent 53 
accessibility; (ii) At the molecular level, PDP overcomes chemotherapy-induced enrichment of 54 
stemness markers to suppress aggressive tumor relapse; and (iii) PDP’s subtumoricidal nature, 55 
distinct mechanism of action, and non-overlapping toxicities, enhance chemotherapeutic efficacy 56 
with no additional side effects in vivo. We provide evidence that a clinically feasible PDP 57 
regimen realizes these complementary interactions to significantly potentiate the efficacy of 58 
multi-cycle nal-IRI, resulting in prolonged local tumor control, reduced metastatic burden, and 59 
enhanced survival outcomes in vivo in two mouse models of human pancreatic ductal 60 
adenocarcinoma (PDAC).  61 
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PDAC is a devastating disease characterized by a dense fibrous stroma, that impedes drug 62 
delivery, and by a profound resistance to standard chemotherapy(8). Therapeutic strategies 63 
designed to ablate this tumor-associated desmoplasia yielded disappointing clinical results(9,10), 64 
in part because PDAC-stroma interactions are extraordinarily complex and incompletely 65 
understood(11). In 2015, nal-IRI combined with 5-fluorouracil and leucovorin was approved to 66 
treat gemcitabine-refractory metastatic PDAC(12). Developed by Drummond and colleagues, 67 
nal-IRI improves the circulation half-life, pharmacokinetics and intratumoral accumulation of 68 
irinotecan and its active metabolite, SN-38, while minimizing toxic side effects(13). The superior 69 
in vivo anti-cancer activity of nal-IRI, as compared to free irinotecan, is related to nal-IRI’s 70 
ability to extend the duration of intratumoral SN-38 above a critical threshold concentration.(14) 71 
However, the high degree of variability in nal-IRI tumor deposition in vivo remains a challenge, 72 
presumably due to the low permeability of liposomes within some tumors, as described 73 
previously(14). Moreover, because PDAC cells are highly resistant to standard chemotherapy(8), 74 
it is increasingly evident that intensive chemotherapeutic regimens based on the maximum 75 
tolerated dose can impose selection pressures that reveal residual populations of intrinsic or 76 
acquired resistant clones, portending a poor outcome(15,16). Prime examples of highly 77 
aggressive PDAC subpopulations include cells that overexpress hyaluronan receptor (CD44) and 78 
C-X-C chemokine receptor type 4 (CXCR4)(17-19). These markers play pivotal roles in self-79 
renewal, multi-lineage differentiation, chemoresistance, potent proliferative and metastatic 80 
capacity of PDAC, and correlate with poor prognosis in patients(17-19). Previous studies have 81 
shown that the front-line chemotherapy for PDAC, gemcitabine, induces a significant increase in 82 
CD44 (17.5-fold) and CXCR4 (20-fold) protein levels in PDAC cell lines(16,20), and enriches 83 
CD44+ cell population by ~40% in patient-derived xenografts and patient samples of PDAC(21). 84 
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Preventing the selection of these aggressive phenotypes while maintaining cytotoxic efficacy 85 
have become highly desirable attributes of any therapeutic regimen. Here, we demonstrate for 86 
the first time that PDP simultaneously increases the local nal-IRI concentration in tumors (by 87 
enhancing tumor permeability transiently), and attenuates the upregulation of CD44 and CXCR4 88 
markers in nal-IRI treated tumors in vivo, leading to superior treatment outcomes in orthotopic 89 
models of PDAC.  90 
PDP is based on the hypothesis that spatiotemporal control of photosensitizer activation 91 
can induce enhanced tumor permeability secondary to singlet oxygen generation in the tumor 92 
vasculature, stroma, and parenchyma. In addition, because PDP is comprised of subtumoricidal 93 
photodynamic therapy (PDT)(22), it has the added advantage of directly activating cancer 94 
apoptosis in such a way that bypasses multiple cell death signaling pathways that are typically 95 
required by conventional chemotherapy regimens to be effective. Kessel et al. first reported that 96 
PDT directly induces photodamage to the mitochondria-associated Bcl-2 protein (a major anti-97 
apoptotic factor and mediator of drug resistance) to release mitochondrial cytochrome c (a potent 98 
pro-apoptotic signal), thereby initiating apoptosis(23). This direct pathway to cell death suggests 99 
that PDT, with sufficient co-localization of photosensitizer and light, is effective even against 100 
chemoresistant populations characterized by defective signaling pathways, and thus may prevent 101 
enrichment of these specific aggressive subpopulations and their associated molecular 102 
characteristics. Building on the recent clinical advances using PDT for locally advanced PDAC 103 
patients(24), our findings offer prospects to design new PDP-based approaches that offer dual 104 
advantages stemming from enhanced drug accessibility while minimizing treatment-induced 105 
molecular selective pressures for long-term anti-tumor efficacy, without additional side effects. 106 
 107 
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Materials & Methods 108 
Nanoliposomal BPD (nal-BPD) and nanoliposomal irinotecan (nal-IRI) preparation. 109 
Nanoliposomal benzoporphyrin derivative (nal-BPD) were prepared via freeze-thaw 110 
extrusion technique as previously described(25). Briefly, dipalmitoylphosphatidylcholine 111 
(DPPC), cholesterol, distearoylphosphatidylethanolamine-methoxy polyethylene glycol (DSPE-112 
PEG), and dioleoyltrimethylammoniumpropane (DOTAP) (Avanti Polar Lipids) were mixed in 113 
chloroform at 20:10:1:2.5 molar ratio. Two hundred micromolars of BPD (U.S. Pharmacopeial 114 
Convention) was dissolved with lipids at a drug-to-lipid ratio of 0.6 mol%. Chloroform was 115 
removed by rotary evaporation overnight to afford a thin lipid film. The resulting lipid film was 116 
rehydrated with 1mL of phosphate-buffered saline at 45°C, and then subjected to freeze-thaw 117 
cycles (4–45°C) for 2 hours. The dispersion was then extruded ten times through 0.1μm 118 
polycarbonate membranes at 42°C using a mini-extruder system to form unilamellar vesicles. 119 
Un-encapsulated BPD photosensitizers were removed by dialysis (MWCO 300kD) against 120 
phosphate-buffered saline. The resulting nal-BPD preparations displayed a particle size of 121 
135nm (Polydispersity index ~0.04) and a photosensitizer loading of 3μg BPD/mmol 122 
phospholipid. Stability, shelf-life, singlet oxygen yield, photobleaching, quenching, drug release, 123 
in vivo pharmacokinetics and biodistribution of nal-BPD were previously reported(25). The 124 
clinically approved nanoliposomal irinotecan (nal-IRI) and DiIC18(5)-DS dye-conjugated nal-125 
IRI (Dil5-nal-IRI) were kindly provided by Merrimack Pharmaceuticals(13). 126 
Cell Culture. 127 
Human PDAC cancer cell lines, MIA PaCa-2 and AsPC-1, were purchased from ATCC. 128 
All cells were authenticated prior to receipt and were propagated for less than four months after 129 
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resuscitation. Cultures were tested for mycoplasma as previously described(25). All cell lines 130 
were cultured in humidified CO2 atmosphere at 37°C using media recommended by the vendor. 131 
Orthotopic mouse model and treatments. 132 
All treatment and care of animals were in accordance with the protocol approved by 133 
Massachusetts General Hospital (MGH) Institutional Animal Care and Use Committee 134 
(IACUC). MIA PaCa-2 or AsPC-1 cells were implanted orthotopically in 4-6 weeks old male 135 
Swiss nude mice (20-25g) to establish xenograft tumors. Animals were anesthetized with 136 
100mg/kg ketamine and 10mg/kg xylazine, and a small left abdominal flank incision was made 137 
to exteriorize the pancreas. Subsequently, a suspension of 1x10
6
 cancer cells in 25μL of chilled 138 
culture media mixed with an equal volume of chilled Matrigel
®
 was injected into the mouse 139 
pancreas, and the incision was sutured aseptically. Treatments were initiated nine days after 140 
cancer cell implantation when tumor volumes reached approximately 50mm
3—determined by 141 
ultrasound imaging (Vevo LAZR; VisualSonics) as previously described(25). Injections of nal-142 
BPD and nal-IRI (20mg/kg, hydrochloride salt) for treatment were done intravenously (tail vein) 143 
in 200μL sterile phosphate-buffered saline. Mice were randomized into groups that received (i) 144 
no-treatment, (ii) photodynamic priming (PDP), (iii) nal-IRI (four cycles on days 9, 12, 17, and 145 
21 after tumor implantation), (iv) single cycle nal-IRI (sc-nal-IRI; one cycle on day 9 after tumor 146 
implantation) (v) PDP+sc-nal-IRI, (vi) PDP+nal-IRI. For sub-tumoricidal PDP, orthotopic 147 
tumors were surgically exposed (as for tumor implantation) at one hour after intravenous 148 
injection of nal-BPD (0.25mg/kg BPD equivalent). Tumors of mice receiving nal-BPD were 149 
irradiated with NIR light using a 690nm diode laser (High Power Devices), delivered at an 150 
irradiance of 100mW/cm
2
 to achieve a fluence of 75J/cm
2
.  Following PDP, the incisions were 151 
closed with 4-0 Ethilon sutures and the animals were allowed to recover. Tumor growth in every 152 
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animal was longitudinally monitored every 3-5 days using non-invasive ultrasound imaging as 153 
described previously. At each time point, tumor volume was calculated using hemiellipsoid 154 
formula (π·L·W·H/6, where L, W and H, are the tumor length, width and height), which was 155 
validated against the three-dimensional volume reconstruction algorithm of the Vevo2100 156 
software(25). To calculate the specific growth rate (SGR) of tumor, the following formula was 157 
used: SGR = (1/V)(dV/dt), where V is tumor volume and t is time. Change in mouse body weight 158 
was monitored before tumor implantation and longitudinally after treatment as a metric of 159 
systemic toxicity. For survival studies, moribundity was used as the endpoint with proper 160 
justification and special approval by MGH IACUC. Progression-free survival (PFS) is 161 
defined as the time from treatment initiation to any increase in tumor volume or death from any 162 
cause. 163 
Pharmacokinetic studies. 164 
When the average tumor volume reached approximately 50 mm
3
, mice were randomized 165 
into groups that received (i) no-treatment, (ii) PDP, (iii) single cycle of nal-IRI at 20mg/kg (sc-166 
nal-IRI; on day 9 after tumor implantation), and (iv) PDP+sc-nal-IRI. At 1, 4, 24, 72, 168 hours 167 
after treatment, mice were euthanized by CO2 asphyxiation followed by blood collection, and 168 
then mice were perfused with phosphate-buffered saline prior to harvesting tumor and other 169 
normal tissues. Bloods samples were collected in tubes containing lithium heparin and were 170 
centrifuged to separate the plasma immediately after sample collection. All samples were stored 171 
at -80°C until analyses. Tumor and plasma were analyzed for irinotecan and SN-38 172 
concentrations using the HPLC method previously described(14). Briefly, tumors were weighed 173 
and homogenized for 2 minutes in 20% w/v water using a TissueLyser (Qiagen). The 174 
homogenates were extracted by mixing 0.1mL homogenate with 0.9mL 1% acetic acid/methanol 175 
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followed by 10s vortexing and placing at −80°C for 1 hour. The samples were centrifuged at 176 
10,000rpm for 10 minutes at room temperature and supernatants collected for HPLC analysis 177 
(Dionex). The samples and standards (irinotecan and SN-38) were analyzed using a C18 reverse 178 
phase column (Synergi Polar-RP 80A 250×4.60 mm 4μm column). The drug metabolites were 179 
eluted running a gradient from 30% acetonitrile; 70% 0.1% TFA/H2O to 68% acetonitrile; 32% 180 
0.1% TFA/H2O during a 13 minutes span at a flow rate of 1.0mL/min. The initial elute 181 
composition was restored after 14 minutes and continued for 6 minutes before the next injection. 182 
The irinotecan peak was detected at ~7.7 minutes and the SN-38 peak eluted at ~8.4 minutes, 183 
using an in-line fluorescence detector excited at 372nm and emitting at 556nm. 184 
Tumor vasculature and Dil5-nal-IRI fluorescence imaging. 185 
Tumor-bearing mice were randomized into groups that receive (i) no-treatment, (ii) nal-186 
BPD, (iii) PDP, (iv) Dil5-nal-IRI, and (v) PDP + Dil5-nal-IRI. At 4, 24, 72 hours after treatment, 187 
mice were intravenous (tail vein) injected with 100μL of Fluorescein-labeled Lycopersicon 188 
esculentum (tomato) lectin (1mg/mL in phosphate-buffered saline, Vector Laboratories) to label 189 
the vascular endothelium. At 5 minutes after tomato-lectin intravenous injection, mice were 190 
euthanized by CO2 asphyxiation followed by perfusion with phosphate-buffered saline prior to 191 
harvesting tumors. Excised tissues were embedded in optimal cutting temperature compound and 192 
frozen at -80°C. A cryotome was used to cut 20-μm-thick cryosections. Sections were mounted 193 
(Invitrogen SlowFade Gold with 4′,6-diamidino-2-phenylindole, DAPI) with a coverslip and 194 
sealed with nail polish for confocal fluorescence imaging (Olympus FluoView 1,000 confocal 195 
microscope) using a 10x0.4 numerical aperture (NA) or a 20x0.75 NA objective. Excitation of 196 
DAPI, tomato-lectin labeled vasculature, and DiIC18(5)-DS dye conjugated nal-IRI (Dil5-nal-197 
IRI) was carried out using 405, 488, and 635-nm lasers, respectively, with appropriate filters.  198 
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Immunofluorescence imaging of CD44 and CXCR4 markers. 199 
Treatment impacts on the tumoral expression of CD44, and CXCR4 were investigated. 200 
Briefly, orthotopic pancreatic tumors were excised on 60 and 120 days after tumor implantation 201 
(i.e. 51 and 111 days after treatment initiation), embedded in optimal cutting temperature 202 
compound and frozen at -80 °C. A cryotome was used to cut 20-μm-thick cryosections. Sections 203 
were (i) fixed in ice-cold 1:1 acetone:methanol for 10 min, (ii) air dried for 30 minutes, and (iii) 204 
washed three times in phosphate-buffered saline. A blocking solution (Dako Protein Block 205 
Reagent) was applied for 30 min followed by application of the immunostains, at ~5μg/mL 206 
monoclonal antibody (MAb) each diluted in background reducing Dako Antibody Diluent for 207 
overnight at 4°C in a humidifying chamber. Finally, the slides were washed again three times, 208 
mounted (Invitrogen SlowFade Gold with 4′,6-diamidino-2- phenylindole, DAPI) with a 209 
coverslip and sealed with nail polish. Confocal fluorescence imaging was performed using an 210 
Olympus FluoView 1,000 confocal microscope with a 10x0.4 numerical aperture (NA) or a 20x 211 
0.75NA objective. Excitation of DAPI, anti-human cytokeratin 8 (clone LP3 K IC3165G; R&D 212 
Systems) MAb-Alexa Fluor 488 conjugates, and anti-human CD44 (clone DB105; Miltenyi 213 
Biotec) MAb- APC-Vio770™ conjugates was carried out using 405-, 405-, and 635-nm lasers, 214 
respectively, with appropriate filters. At least 10 images, evenly distributed across the entire 215 
tumor cross-section, were collected from 3 tumor samples for each condition. 216 
Western Blot. 217 
Protein expression was analyzed using a standard Western protocol (Bio-Rad). As briefly 218 
described, tissue lysates (10μg) were separated on 10% precast polyacrylamide gel (Mini-219 
PROTEAN TGX, Bio-Rad) and transferred onto PVDF membrane (Thermo). Subsequent to 220 
blocking with 5% milk/TBST solution, proteins were further detected using antibodies against 221 
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CD44 (1:1000, Santa Cruz sc7946), CXCR4 (1:500, Abcam ab93478), and E-Cadherin (1:500, 222 
Abcam ab15148). Anti GADPH antibodies (1:5000, Cell Signaling 2118S) were used for loading 223 
control. Visualization of protein bands was developed by chemiluminescence (ECL, Bio-Rad) 224 
with exposure to X-ray film (Thermo). The quantitative analysis of protein expression was done 225 
using ImageJ software. Western blot analyses of target proteins were repeated at least for three 226 
times. 227 
Measurement of metastatic burden. 228 
A quantitative reverse transcription-polymerase chain reaction (qRT-PCR) assay was 229 
performed on excised liver, lung, diaphragm, and paraaortic lymph nodes to estimate the number 230 
of human cancer cells in excised organs as described and validated previously(26). Briefly, qRT-231 
PCR is used to measure the total number of human cancer cells from the level of human and 232 
mouse glyceraldehyde 3-phosphate dehydrogenase (GAPDH) housekeeping genes. The entire 233 
freshly excised liver, lung, diaphragm, paraaortic lymph nodes were collected at the treatment 234 
endpoint and snap frozen in liquid nitrogen. The frozen samples were then pulverized and 235 
homogenized in TRIzol solution, followed by RNA extraction (RNAeasy Plus Mini Kit; 236 
Qiagen). Human and mouse GAPDH gene were measured using custom synthesized primers 237 
(Invitrogen). For each specimen, the cycle threshold (Ct) from human GAPDH gene was 238 
quantified into number of cancer cells using a standard curve generated with a set of organ 239 
lysates from no-tumor control mice mixed with different numbers of human cancer cells. 240 
Statistical analyses. 241 
Results are mean ± standard error of the mean (SEM). Statistical tests were carried out 242 
using GraphPad Prism (GraphPad Software). Specific tests are indicated in the figure captions. 243 
All reported P values are two-tailed. In vivo results and fluorescence intensity analyses were 244 
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analyzed using nonparametric tests (the Bonferroni-corrected Mann-Whitney U test or Kruskal–245 
Wallis one-way ANOVA with appropriate post hoc test); the D’Agostino & Pearson omnibus 246 
normality test (α=0.05; requires n ≥ 8 replicates per group to perform testing) identified 247 
deviations from normality within these data sets. One-way ANOVA was applied to test for 248 
longitudinal treatment interactions, based on the linearized slope of each tumor volume growth 249 
curve. Log-transformation was applied to linearize the tumor volume growth curve for each 250 
animal. No exclusion criteria were used, and no data points or animals were excluded from 251 
analysis. Two-way ANOVA was also applied to test for synergistic treatment interactions, using 252 
the slope of each tumor volume growth curve; log-transformation was applied to linearize the 253 
tumor volume growth curve for each animal. No exclusion criteria were used, and no data points 254 
or animals were excluded from analysis. Survival curves were created using the method of 255 
Kaplan and Meier. The log-rank test was used to test if the difference between survival times 256 
between two groups is statistically significant or not. Investigators were blinded to experimental 257 
groups during tumor volume monitoring and survival studies unless noted otherwise. 258 
259 
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Results  260 
PDP induces physiological changes in vascular permeability to enhance the tumor 261 
pharmacokinetics of nal-IRI. 262 
To evaluate PDP-mediated changes in tumor vascular permeability, DiIC18(5)-DS dye-263 
conjugated nal-IRI (Dil5-nal-IRI) was administered by intravenous injection in mice bearing 264 
orthotopic MIA PaCa-2 tumors (50mm
3
). Confocal imaging showed PDP enhanced Dil5-nal-IRI 265 
extravasation and accumulation in tumors at 4 hours after Dil5-nal-IRI injection (Fig.2A). 266 
Without PDP, only a small amount of Dil5-nal-IRI extravasated along the immediate vicinity of 267 
tumor blood vessels at an average distribution area of 0.002mm
2
 at 4 hours after injection. In 268 
contrast, PDP significantly broadened the intratumoral dissemination of Dil5-nal-IRI along the 269 
periphery of blood vessels by 100 times to 0.220.02mm2 (P<0.001; Fig.2B). Furthermore, Dil5-270 
nal-IRI was highly retained in PDP-treated tumors for at least 24-hours (Fig.2C). The ratio of the 271 
fluorescence signal intensities (FSI) of accumulated Dil5-nal-IRI at 4 and 24 hours after injection 272 
was found to be 6.2 and 10-fold higher in the PDP-treated tumors, respectively (Fig.2C; 273 
P<0.001), compared to the control tumors using the following equation: (FSIPDP+Dil5-nal-IRI–FSIno-274 
treatment)/(FSIDil5-nal-IRI–FSIno-treatment). 275 
Irinotecan is a camptothecin prodrug that is converted by carboxylesterases to produce 276 
the active SN-38 (7-ethyl-10-hydroxycamptothecin) metabolite, which is approximately 100 to 277 
1000-fold more potent(27). The tumoral irinotecan and SN-38 pharmacokinetic profiles of nal-278 
IRI were evaluated with and without PDP (Fig.2D,E). In the orthotopic MIA PaCa-2 model, 279 
intravenous administration of a single cycle of nal-IRI (20mg/kg irinotecan hydrochloride salt) 280 
resulted in 0.35%ID/g (1390ng/g) of tumoral irinotecan 24 hours after injection (Fig.2D). In 281 
contrast, following PDP+nal-IRI, intratumoral irinotecan levels were 11-fold higher (3.5%ID/g) 282 
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and remained above 1%ID/g for 72 hours (Fig.2D). Similarly, SN-38 cleared earlier from the 283 
tumors following nal-IRI injection to 12.8ng/g (32.6nM) within 24 hours, while ‘PDP+nal-IRI’ 284 
treated tumors exhibited a high intratumoral SN-38 level of above 50ng/g (127.4nM) for up to 285 
72-hours following treatment (Fig.2E). PDP did not alter tumor carboxylesterase activity 286 
(Fig.2F), as a result the time-dependent change in the molar ratio of irinotecan-to-SN-38 in 287 
tumors treated with nal-IRI was similar to the ‘PDP+nal-IRI’ group (Fig.2G). 288 
PDP of local tumors followed by multi-cycle nal-IRI prevents rapid tumor regrowth and 289 
synergistically enhances long-term tumor growth inhibition. 290 
To assess the efficacy of PDP and nal-IRI in controlling localized tumors in vivo, 291 
treatments were performed nine days following orthotopic implantation of MIA PaCa-2 or 292 
AsPC-1 human PDAC cells in mice, when tumors reached approximately 50mm
3
 in volume. The 293 
following treatments were randomly administered to mice: (i) no-treatment; (ii) PDP; (iii) nal-294 
IRI; and (iv) PDP+nal-IRI (Fig.3A). For PDP, light (690nm) irradiation was performed one hour 295 
after a single intravenous injection of a nanoliposomal formulation of the photosensitizer, 296 
benzoporphyrin derivative (nal-BPD at 0.25mg/kg), to induce sub-tumoricidal tumor 297 
permeabilization. The 1-hour photosensitizer-light interval was used to achieve a balanced 298 
distribution of nal-BPD in both the tumor vasculature and parenchyma, based on our previous 299 
experience(28). Four intravenous injections of nal-IRI were administered over two weeks, and 300 
each injection contained 20mg/kg irinotecan hydrochloride salt. Tumor growths were 301 
longitudinally monitored using non-invasive ultrasound imaging. In MIA PaCa-2 tumors 302 
(derived from a primary tumor), both ‘PDP+nal-IRI’ and ‘nal-IRI’ exhibited a significant 303 
inhibition of tumor growth during the treatment period, whereas, continued tumor growth was 304 
observed in ‘no-treatment’ and ‘PDP’ over this same period (Fig.3B-D). At 30 days post-305 
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implantation, the mean tumor volume reduction in mice treated with ‘nal-IRI’ and ‘PDP+nal-306 
IRI’ was 89% and 96%, respectively, compared to ‘no-treatment’ animals (Fig.3C). However, 307 
shortly after termination of treatment and up to 120 days following implantation, animals treated 308 
with ‘nal-IRI’ experienced a rapid tumor regrowth at a specific growth rate (SGR) of 309 
4.80.3%/day, which is significantly higher than the 2.60.2%/day SGR in ‘no-treatment’ 310 
(P<0.05; Fig.3E). In contrast, ‘PDP+nal-IRI’ not only significantly inhibited tumor volume 311 
growth by 96% by day 32 (with a SGR of –4.71%/day) (Fig.3D), but also continued to suppress 312 
tumor growth at an SGR of 1.70.9%/day for a prolonged period of up to 120 days (Fig.3E). The 313 
effect of ‘PDP+nal-IRI’ on tumor growth inhibition was found to be highly synergistic compared 314 
to monotherapies (P=0.0041; Fig.S1). Furthermore, mouse body weight was longitudinally 315 
monitored before and after treatment as a metric of toxicity (Fig.S2). In ‘PDP+nal-IRI’ animals, 316 
the change in mouse weight was consistent with ‘nal-IRI’ mice, indicating that PDP does not 317 
appreciably add to the in vivo systemic toxicity. The gain in mouse weight after single cycle nal-318 
IRI was comparable to the combination of PDP and a single cycle nal-IR, whereas, a transient 319 
loss in mouse weight up to 8% was observed following four cycles of nal-IRI treatment both in 320 
presence and absence of PDP. These observations suggest that the sub-tumoricidal PDP 321 
approach does not further increase the systemic toxicity of nal-IRI in mice. The long-term 322 
efficacy of ‘PDP+nal-IRI’ was also evaluated in a model for more aggressive PDAC using 323 
AsPC-1 cells derived from a metastatic lesion (Fig.3F-I). In agreement with the literature, AsPC-324 
1 tumors in ‘no-treatment’ controls exhibit a significantly higher tumor SGR (10.90.4%/day), 325 
compared to MIA PaCa-2 tumors (6.70.7%/day) (P=0.0025). Both ‘nal-IRI’ and ‘PDP+nal-IRI’ 326 
significantly reduced AsPC-1 tumor volume growth for at least 30 days, but did not completely 327 
arrest tumor growth (Fig.3E-G). However, between days 30 and 120, AsPC-1 tumors that 328 
Research. 
on December 12, 2017. © 2017 American Association for Cancercancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on November 29, 2017; DOI: 10.1158/0008-5472.CAN-17-1700 
 17 
received ‘PDP+nal-IRI’ exhibited a much lower regrowth rate (3.70.7%/day), compared to ‘no-329 
treatment’ (~6%/day) (P<0.05; Fig.3H). Ultimately, combining PDP with nal-IRI resulted in 330 
superior AsPC-1 volume control compared to the nal-IRI treated tumors at day 120 (P<0.05; 331 
Fig.3D). 332 
PDP overcomes chemotherapeutic selection pressures that cause upregulation of cancer stem 333 
cell markers and dedifferentiation. 334 
To assess whether the rapid MIA PaCa-2 tumor regrowth following four cycles of nal-IRI 335 
observed in figure 3B occurred as a result of chemotherapeutic selection pressures, we assessed 336 
the expression of CD44, CXCR4, and E-Cadherin, which are associated with tumor progression, 337 
stemness and differentiation. Tumors were harvested at days 60 and 120 following implantation 338 
because they approximated the time-points of significant post-treatment tumor regrowth for the 339 
‘nal-IRI’ and ‘PDP+nal-IRI’ groups, respectively (Fig.3B). Immunofluorescence imaging 340 
(Fig.4A) revealed that four cycles of nal-IRI treatment significantly enriched CD44 and CXCR4 341 
expression by ~180% compared to the ‘no-treatment’ tumors at day 60 (P≤0.05; Fig.4B,C). In 342 
contrast, PDP alone did not promote CD44 and CXCR4 expression of in MIA PaCa-2 tumors. 343 
Interestingly, ‘PDP+nal-IRI’ not only significantly reduced the expression of CD44 (~65-80% 344 
reduction; P≤0.01) compared to the monotherapies, but it also maintained CXCR4 expression at 345 
the base line level by day 60. Similarly at day 120, confirmed by western blot (Fig.4D,E), the 346 
expression of CD44 and CXCR4 were ~2 folds higher in the nal-IRI treated tumors compared to 347 
the ‘no-treatment’ and ‘PDP alone’ groups. In contrast, ‘PDP+nal-IRI’ was able to maintain 348 
CD44 and CXCR4 expressions at a baseline level despite tumor growth after treatment. Tumoral 349 
CD44+, CXCR4+, and CD44+/CXCR4+ cell populations were evaluated by 350 
immunofluorescence double staining at days 60 day 120 (Fig.4F). At day 120 (Fig.4G), nal-IRI 351 
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treatment increased the tumoral CD44+, CXCR4+, and CD44+/CXCR4+ areas by ~1.22, 1.59 352 
and 2 folds, respectively, compared to no-treatment tumors. Both ‘PDP’ and ‘PDP+nal-IRI’ 353 
significantly reduced CD44+, CXCR4+, and CD44+/CXCR4+ cell populated areas by ~43, 71 354 
and 90% respectively, compared to ‘nal-IRI’ treated tumors. At day 60, immunoblotting showed 355 
that nal-IRI treated tumors exhibited the highest level of E-cadherin expression (Fig.4H,I) 356 
relative to all other groups. However, at day 120, ‘no-treatment’, ‘PDP’, and ‘nal-IRI’ tumors 357 
exhibited a complete loss of E-Cadherin expression, whereas a strong expression of E-Cadherin 358 
was observed in the ‘PDP+nal-IRI’ group. These data suggest that at early time points (day 60), 359 
with chemotherapy alone there is evidence of E-Cadherin enriched population. However as the 360 
disease progresses (day 120) only the combination of PDP and nal-IRI overcomes 361 
chemotherapy-induced selection pressures, as evidenced by decreased levels of the stemness 362 
markers CD44 and CXCR4 and increased expression of E-Cadherin. To investigate whether this 363 
time-dependent shift towards a population distribution with a less stem-like and a more 364 
differentiated phenotype may reduce tumor spread and improve outcomes, we evaluated 365 
metastases control and long-term (>1 year) survival benefit of ‘PDP+nal-IRI’. 366 
PDP of primary tumors enhances nal-IRI chemotherapeutic control of metastases. 367 
Locally advanced PDAC often metastasizes to distant organs. Our orthotopic mouse 368 
model of PDAC resembles typical clinical patterns of dissemination, displaying (i) extensive 369 
primary tumor growth that extends to the stomach and duodenum, (ii) metastatic infiltrates to the 370 
liver, and (iii) distant metastases to the retroperitoneal lymph nodes, diaphragm and lung 371 
(Fig.S3). The impact of combining PDP with four cycles of nal-IRI on metastasis control was 372 
evaluated in mice bearing orthotopic MIA PaCa-2 tumors (Fig.5A). At day 60, both ‘PDP+nal-373 
IRI’ and ‘nal-IRI’ significantly reduced the liver and distant organ metastatic burden by at least 374 
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22,000-fold, as compared to the ‘no-treatment’ group (Fig.5B,C). Subtumoricidal PDP alone did 375 
not significantly reduce the metastatic burden, compared to the ‘no-treatment’ (Fig.5B,C). These 376 
results suggest that the metastatic disease is primarily and effectively controlled by ‘nal-IRI’ at 377 
early time points. At day 60, both ‘nal-IRI’ and ‘PDP+nal-IRI’ completely inhibited liver 378 
metastasis and significantly reduced distant organ (lung, diaphragm, lymph node) metastases to 379 
less than 50 cancer cells, compared to ‘no-treatment’ mice (>1 million cancer cells at lung, 380 
diaphragm, lymph node) (Fig.5D). Importantly, the benefit in controlling metastases provided by 381 
nal-IRI alone over 60 days was lost by day 120. Only ‘PDP+nal-IRI’ achieved a significant 382 
reduction in the overall and distant organ metastases by an average of ~16,000-fold and ~40,000-383 
fold (P<0.01), respectively, compared to ‘no-treatment’ (Fig.5D). In contrast, metastatic burden 384 
in ‘nal-IRI’ group was not significantly different from ‘no-treatment’ mice at day 120 (Fig.5D). 385 
In addition to metastatic burden, the incidence of metastases in MIA PaCa-2 mouse model was 386 
monitored at days 60 and 120. At day 60 (when diaphragm metastases were observed in 100% of 387 
animals), ‘PDP+nal-IRI’ significantly reduced the incidence of diaphragm metastases by 66%, 388 
while ‘nal-IRI’ did not reduce the incidence of metastasis (Fig.5E). Consistent with the 389 
metastatic burden data, by day 120, the incidence of liver, lung, and lymph node metastases in 390 
the ‘PDP+nal-IRI’ mice was dramatically reduced to 6.7% and 33%, respectively, in contrast to 391 
the high incidence of liver and distant metastases (60-100%) for the ‘no-treatment’, ‘PDP’, and 392 
‘nal-IRI’ groups (Fig.5E). 393 
PDP and multi-cycle nal-IRI prolong survival and reduce endpoint disease burden in two 394 
PDAC models. 395 
Most patients with PDAC are diagnosed at an advanced stage and rapidly succumb to 396 
their disease. It was, therefore, critical to determine if the significant and prolonged improvement 397 
Research. 
on December 12, 2017. © 2017 American Association for Cancercancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on November 29, 2017; DOI: 10.1158/0008-5472.CAN-17-1700 
 20 
in metastasis control provided by ‘PDP+nal-IRI’ translated to durable survival enhancement. 398 
Using moribundity as the endpoint (Fig.6A),  the orthotopic models of MIA PaCa-2 and 399 
AsPC-1 cells demonstrated median survival times of 146 days (4.9 months) and 82.5 days 400 
(2.75 months), respectively (Fig.6B-D). In the MIA PaCa-2 model, sub-tumoricidal PDP 401 
combined with four cycles of nal-IRI significantly prolonged the median overall survival 402 
(OS) to 280 days (9.3 months), compared to 170 days (5.6 months) with ‘nal-IRI’ (Fig.6B; 403 
P<0.01). All animals in the ‘no-treatment’ and ‘nal-IRI’ groups were dead at days 228 and 404 
215, respectively. In the ‘PDP’ group, 92% of the mice died by day 208, while 1 out of 13 405 
(8%) survived to day 337. Importantly, 25% of animals in the ‘PDP+nal-IRI’ group survived 406 
to day 450 (~1.23 years), when the study was terminated.  The pancreas and distant organs in the 407 
mice treated with ‘PDP+nal-IRI’ were confirmed to be tumor-free by ultrasound imaging, 408 
complete necropsy, and qRT-PCR (see Methods). Combined PDP and multi-cycle nal-IRI 409 
doubled the median progression-free survival (PFS) of MIA PaCa-2 tumor-bearing mice to 76 410 
days (2.53 months), compared to the PSF of mice treated with ‘nal-IRI’ (35 days) (P<0.001; 411 
Fig.6C). It is noteworthy that although the combination of PDP and a single cycle of nal-IRI, 412 
synergistically reduced acute tumor burden (Fig.S1), no survival benefit was observed (Fig.S4). 413 
These findings highlight the difficulty in achieving meaningful improvements in treatment 414 
response for PDAC and emphasize the need for combination regimens designed to provide 415 
durable tumoricidal control. In the AsPC-1 model, combined PDP and four cycles of nal-IRI 416 
achieved ~18% tumor-free animal survival and significantly prolonged the median OS of mice to 417 
214 days (7.1 months), compared to 82.5 days (~2.75 months) in ‘no-treatment’ mice (P=0.024; 418 
Fig.6D). Although the mice treated with nal-IRI also demonstrated an improved median OS of 419 
170 days (5.6 months), it was found to be non-significant (P=0.3) compared to the ‘no-420 
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treatment’ mice. These results, in two animal models, suggest that sub-tumoricidal PDP of 421 
primary tumors is crucial to achieving significant and durable survival benefits with nal-IRI. The 422 
forest plot (Fig.6E) summarizes the hazard ratio data across multiple variables. Here, the 423 
hazard ratio is defined as the ratio of the probability of death in the treatment arm to the 424 
probability in the no-treatment arm, and represents the instantaneous risk over the study 425 
time period. A hazard ratio of less than 0.2 (P<0.05) observed in the ‘PDP+nal-IRI’ group in 426 
both MIA PaCa-2 and AsPC-1 models, suggests that animals in ‘PDP+nal-IRI’ group at any 427 
given time point were five times more likely to survive by the next time point compared to the 428 
no-treatment group. In contrast, all other treatment groups cross the 1.0 value, indicating the 429 
hazard ratio is not significant and there is no clear advantage for ‘PDP’ and ‘nal-IRI’ alone 430 
compared to the ‘no-treatment’ arm.  431 
We further evaluated the primary tumor weight, ascitic fluid volume, and metastatic 432 
burden of animals that reached the moribundity endpoint (excluding tumor-free animals). We 433 
observed that ‘PDP+nal-IRI’ reduced primary tumor weight by 50% in these mice, compared to 434 
tumors treated with nal-IRI alone (P=0.056; Fig.6F). Furthermore, ‘nal-IRI’ and ‘PDP+nal-IRI’ 435 
significantly reduced the mean ascitic fluid volume to 1.20.6 mL (P≤0.05; Fig.6G), compared 436 
to the substantial ascitic fluid accumulation (7.61.2 mL) observed in the ‘no-treatment’ and 437 
‘PDP’. Metastatic burden in mice that reached moribundity was similar in both the ‘PDP+nal-438 
IRI’ and ‘nal-IRI’ (Fig.S5). 439 
440 
Research. 
on December 12, 2017. © 2017 American Association for Cancercancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on November 29, 2017; DOI: 10.1158/0008-5472.CAN-17-1700 
 22 
Discussion  441 
Nanoliposomal delivery systems offer tools to improve the pharmacokinetic and safety 442 
profiles of cytotoxic drugs(29). Nal-IRI, with a favorable irinotecan pharmacokinetic profile, is 443 
presently being incorporated into standard treatment paradigms for patients with gemcitabine-444 
refractory metastatic PDAC, due to manageable safety and substantial improvement in survival 445 
outcomes(7,12). Previously, we have employed photochemistry to damage multidrug efflux 446 
transporter proteins, thereby increasing the intracellular accumulation of nal-IRI in cancer 447 
cells.(25) Here, we introduce the concept of subtumoricidal photodynamic priming (PDP) and 448 
demonstrate its ability to (i) acutely enhance the intratumoral distribution of nal-IRI by covering 449 
100-fold greater portion of the tumor volume, (ii) elevate intratumoral nal-IRI concentrations up 450 
to 11-fold at 24 hours after nal-IRI injection, (iii) maintain high intratumoral SN-38 451 
concentrations for an extended period of 72 hours. Further investigations into the role of PDP in 452 
disrupting and permeabilizing the tumor-associated extracellular matrix are warranted to fully 453 
exploit this approach as a tool to modulate primary tumor permeability and enhance cytotoxic 454 
drug penetration. Importantly, the spatiotemporal selectivity of PDP—achieved by both passive 455 
accumulation of non-toxic photosensitizers and light delivery using optical fiber technology—456 
helped confine this enhanced delivery and pharmacokinetic benefit to the desired disease sites, 457 
thereby limiting undesired systemic off-target toxicities. This multi-layered selectivity limits the 458 
adverse events typically seen in clinical PDAC to mild abdominal pain, skin irritation, and 459 
photosensitivity(24); all of which are non-overlapping with the major side effects of nal-IRI (e.g. 460 
neutropenia and diarrhea)(7), thus affording a compelling, if often overlooked, rationale to 461 
photochemically prime the tumors for nal-IRI. In addition, clinically approved dosing of nal-IRI 462 
for PDAC patients is 70 mg/m
2
, and comprises an average of 5.875 cycles (30). In two 463 
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preclinical in vivo orthotopic mouse models, we show that superior outcomes could be achieved 464 
with PDP followed by four cycles of nal-IRI at clinically relevant dose of 20 mg/kg (equivalent 465 
to human dose ~60 mg/m
2
) over several weeks without compromising nal-IRI efficacy or 466 
increasing off-target toxicities. The long-term durability (weeks) of the effect of PDP in 467 
enhancing drug delivery is not yet clear, combination of periodic PDP and multi-cycle nal-IRI 468 
could potentially further prolong the chemotherapeutic retention in tumors and merits a 469 
comprehensive investigation. Furthermore, advances of multi-drug nanoliposomal formulations 470 
coupled with targeted co-delivery of photosensitizers and chemotherapeutic agents hold high 471 
potential for periodic PDP-based combination therapy to further improve therapeutic outcomes 472 
in the future(26,31). 473 
Although clinical chemotherapy regimens can appear to be quite effective for advanced 474 
PDAC during the treatment period, the use of these intensive treatments at the maximum 475 
tolerated dose may allow for the competitive release and unopposed proliferation of resistant 476 
cancer cell populations(32,33). In our study, four cycles of nal-IRI effectively arrested local 477 
tumor growth and reduced metastatic burden for two months in orthotopic PDAC mouse models. 478 
At one month following treatment termination, a rapid aggressive disease relapse occurred in the 479 
MIA PaCa-2 model, but not in AsPC-1. This variation in treatment response is not surprising, as 480 
the two cells lines are of different origin and characteristics. MIA PaCa-2 cells, are characterized 481 
to be CD44+, CD24− and CD133/1−(34,35), and were derived from the pancreas of a patient 482 
without prior treatments(36). On the other hand, AsPC-1 cells (CD44+, CD24−)(37) were 483 
obtained from the ascites of a metastatic PDAC patient whose disease had already failed both 484 
radiation and chemotherapy(36). Not surprisingly these cells express higher levels of CD44(37), 485 
greater tumorigenicity and chemoresistance(36,38). While first-line gemcitabine chemotherapy 486 
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induces up to 20-fold increase in CD44 and CXCR4 expressions in PDAC cell lines(16,20), we 487 
showed that the MIA PaCa-2 tumor relapse following multi-cycle nal-IRI treatment was 488 
accompanied by 2 folds increase in the tumoral expression of the CD44 and CXCR4 cancer 489 
stem-like cell markers. A number of carefully thought-out regimens exploiting the evolutionary 490 
dynamics of cancer progression have been proposed for more durable outcomes. Since Fidler and 491 
Ellis proposed that “Cancer is a chronic disease and should be treated like other chronic 492 
diseases” in 2000(39), new drug administration and therapeutic modalities have been introduced. 493 
Most notable amongst these regimens are Hanahan’s “metronomic therapy”(40), Folkman, 494 
Kerbel and others studies of using anti-angiogenic therapy to “turn cancer into a manageable 495 
chronic disease”(41,42), Gatenby’s “adaptive therapy”(43), as well as the “evolutionary double 496 
bind” and “stemming tumor growth” methods(44). However, the actual benefits of these 497 
approaches have not yet been confirmed in large-scale clinical trials, presumably because 498 
regimens are cumbersome, labor-intensive, and expensive. Here, for the first time, we show that 499 
the agnostic nature of PDP modulates all cells alike, mitigating the enrichment of stemness 500 
markers (CD44 and CXCR4) and preserving the expression of differentiation markers (E-501 
Cadherin), thereby preventing rapid tumor regrowth and extending the period of tumor growth 502 
inhibition. Enrichment in the CD44 and CXCR4 markers represents an unintended “Achilles' 503 
heel” for current chemotherapy regimens, and both markers are emerging as potential targets for 504 
PDAC treatment(3). The ability of PDP to effectively modulate these markers offers a unique 505 
opportunity to potentially alter cancer cell-stromal cell crosstalk, reverse chemoresistance, and 506 
inhibit metastases. 507 
Clinical studies of treatment failure patterns in PDAC patients have revealed that 508 
approximately 30% of patients died with locally destructive disease, whereas 70% died with 509 
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widespread metastatic disease that most commonly involves the liver in combination with 510 
peritoneal and/or lung metastases(45). Systemic nal-IRI chemotherapy appears to be very 511 
effective in controlling metastases already, and the PDP approach not only sensitizes primary 512 
tumors to nal-IRI for a prolonged acute control, but also further reduced metastatic burden. 513 
Typically, tumoricidal photodynamic therapy (PDT) can also elicit distant anti-tumors effects 514 
due to the immune stimulation(46), and the fact that our in vivo models used in this study were 515 
immunocompromised suggests that the indirect metastatic control afforded by sub-tumoricidal 516 
PDP is secondary to its ability to simultaneously inhibit CXCR4 expression (a crucial driver for 517 
the metastatic phenotype in PDAC) and metastatic escape. Further investigations of PDP in 518 
immunocompetent animals to elicit distant anti-tumor immunity are likely to result in superior 519 
outcomes that better reflect those that would be seen clinically.  520 
Because PDAC is usually diagnosed at an advanced stage and most patients die within 521 
two years of diagnosis(47), maximizing quality of life through effective palliative treatments is a 522 
critical, and often overlooked, endpoint in preclinical settings(48). The quality of life of the 523 
PDAC patient is often impaired by (i) side effects of chemotherapy or pain(49), (ii) extensive 524 
primary tumor growth disrupting digestive processes (e.g. mass effects affecting the intestines or 525 
bile ducts), and (iii) ascites causing abdominal swelling(50). While chemotherapy-induced 526 
toxicities can often be medically managed, the latter two may require palliative surgical 527 
interventions and extended hospitalization. We show that a single dose of PDP followed by 528 
multiple cycles of nal-IRI not only achieved 18-25% tumor-free status in extended survival 529 
studies (300-450 days) in two orthotopic PDAC models, but also effectively reduced the 530 
endpoint disease burden (both primary tumor weight and the ascites volume). These findings 531 
suggest that combination PDP+nal-IRI has the potential to achieve durable improvements in 532 
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treatment response while significantly improving quality of life in PDAC patients, for whom 533 
innovative therapeutic approaches are desperately needed. It is worth mentioning that we 534 
demonstrated nal-IRI alone had no statistically significant survival benefit over the 'no-treatment' 535 
arm in two human orthotopic models. This is not too surprising, as nal-IRI is, so far, only 536 
approved in combination with 5-fluorouracil and leucovorin to treat gemcitabine-refractory 537 
metastatic PDAC. Moreover, a slightly lower dose of nal-IRI (20 mg/kg mouse dose; equivalent 538 
to ~60 mg/m
2
 human dose, a total of 4 cycles) was used in or in vivo study, compared to 539 
clinically approved dose (70 mg/m
2
; an average of ~6 cycles). Further research to assess the 540 
therapeutic effects of combining PDP with the second-line (nal-IRI + 5-fluorouracil + 541 
leucovorin) or front-line (FOLFIRINOX) chemotherapies is warranted. 542 
In summary, we suggest that cancers, which are dynamic evolutionary systems exhibiting 543 
significant physical barriers to effective drug delivery, may be better managed by PDP combined 544 
with chemo or biologic agents. Sub-tumoricidal PDP offers a unique solution to address these 545 
obstacles, showing promise for clinical translation to improve therapeutic accessibility and 546 
address undesired chemotherapeutic selective pressures for a long-term survival benefit in PDAC 547 
models. Given that the feasibility of PDT has already been demonstrated in early PDAC clinical 548 
trials(24), leveraging our PDP approach to address the evolutionary challenges associated with 549 
standard chemotherapy and increased permeability to enhance the therapeutic index of 550 
conventional agents merits further investigations at preclinical and clinical levels. 551 
552 
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Figure Legends:  707 
Fig.1. Concept of sub-tumoricidal photodynamic priming. Spatiotemporally controlled 708 
photodynamic priming (PDP) of tumor microvasculature and parenchyma simultaneously 709 
improves therapeutic agent accessibility and overcomes chemotherapeutic selection 710 
pressures. Subtumoricidal PDP increases tumor permeability to enhance intratumoral 711 
accumulation of chemotherapeutic agents for a prolonged period of time. In addition, it 712 
attenuates the insidious surge of stemness marker expression that is typically observed 713 
after multiple cycles of chemotherapy. Combining subtumoricidal PDP with cytotoxic 714 
chemotherapeutic agents prevents aggressive tumor regrowth, reduces metastatic burden, 715 
and enhances survival outcomes. 716 
Fig.2. PDP increases tumor vascular permeability to enhance nal-IRI delivery in an orthotopic 717 
PDAC model. Orthotopic MIA PaCa-2 tumors were exposed to 75 J/cm
2
 of light (100 718 
mW/cm
2
) one-hour following intravenous injection of nal-BPD (0.25 mg/kg) and a single 719 
dose of Dil5-nal-IRI (20 mg/kg). Control tumors were only injected with Dil5-nal-IRI (20 720 
mg/kg) without light treatment. (A) Representative confocal fluorescence microscopy 721 
images of control tumors (top row) and PDP-treated tumors (bottom row) obtained 4 722 
hours after intravenous injection Dil5-nal-IRI. In presence of PDP, Dil5-nal-IRI (red) was 723 
widely distributed throughout the tumor tissue and extravasated from the blood vessels 724 
(tomato lectin staining; green), whereas the signals arising from Dil5-nal-IRI in control 725 
tumors were confined to the immediate vicinity of the tumor blood vessels. No Dil5-nal-726 
IRI signal was detected in the tumors treated with PDP alone. Nuclear staining (blue-727 
fluorescence, DAPI); Scale bar 200 μm. (B, C) Quantitative analyses of Dil5-nal-IRI 728 
fluorescence intensity (B) and distribution (C) showing PDP significantly enhanced Dil5-729 
Research. 
on December 12, 2017. © 2017 American Association for Cancercancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on November 29, 2017; DOI: 10.1158/0008-5472.CAN-17-1700 
 32 
nal-IRI accumulation and extravasation within MIA PaCa-2 tumors 4 and 24 hours after 730 
Dil5-nal-IRI injection (n ≥ 3 animals per group; n ≥ 19 images per group; ***P<0.001, 731 
Bonferroni-corrected Mann-Whitney U test). (D, E) PDP mediated changes in tumor 732 
pharmacokinetic profile of nal-IRI. Swiss nude mice bearing orthotopic MIA PaCa-2 733 
tumors were treated with a single cycle of nal-IRI (nal-IRI, 20 mg/kg; IV) (red line; solid 734 
square) or a combination of PDP and single cycle nal-IRI (20 mg/kg; IV) (blue line; solid 735 
circle). Tumors were collected at various intervals and the irinotecan (d) and SN-38 (e) 736 
levels were measured by HPLC analysis (n ≥ 5 per time point; ***P<0.01, **P=0.022, 737 
*P<0.05, Bonferroni-corrected Mann-Whitney U test). (F) Carboxylesterase (CES) 738 
activities in MIA PaCa-2 tumors were not modulated by PDP at various time posts after 739 
treatment (n = 3-9 animals per condition; ns, non-significant, Kruskal–Wallis one-way 740 
ANOVA). (G) Comparison of tumoral irinotecan to SN-38 molar ratio at various time-741 
points between ‘single cycle nal-IRI’ monotherapy and ‘PDP + single cycle nal-IRI’ arm. 742 
(n ≥ 5 per time point; Solid lines are nonlinear fits; n.s., non-significant, P=0.79, two-way 743 
ANOVA PDP·time interaction term). Results are mean ± standard error of the mean 744 
(SEM). 745 
Fig.3. PDP of tumors extends the efficacy of multi-cycle nal-IRI chemotherapy for durable 746 
tumor control in two orthotopic PDAC models. (A) In vivo treatment schedule: 747 
Treatments were initiated nine days after MIA PaCa-2 or AsPC-1 cancer cell 748 
implantation when tumor volumes reached approximately 50 mm
3
 (see Methods). Mice 749 
were randomized into groups that received (i) no-treatment, (ii) PDP (nal-BPD 0.25 750 
mg/kg; 690 nm light at 100 mW/cm
2
 to achieve 75 J/cm
2
), (iii) nal-IRI (four doses, each 751 
at 20 mg/kg irinotecan hydrochloride salt, on days 9, 12, 17, and 21 after tumor 752 
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implantation), and (iv) combination of PDP and nal-IRI (PDP+nal-IRI). Injections of nal-753 
BPD (for PDP) and nal-IRI were done intravenously. (B-E) Orthotopic MIA PaCa-2 and 754 
(F-I) AsPC-1 tumor volumes were longitudinally monitored by non-invasive ultrasound 755 
imaging. A combination of PDP and nal-IRI prolonged and enhanced tumor growth 756 
inhibition in both MIA PaCa-2 and AsPC-1 animal models compared to nal-IRI alone. (n 757 
= 9-13 for MIA PaCa-2 model; n = 5-7 for AsPC-1 model; *P<0.05, ***P<0.001, one-758 
way ANOVA with Tukey’s post hoc test for ‘nal-IRI’ vs. ‘PDP+nal-IRI’ groups). (C, G) 759 
Gross tumor volume changes were quantified between day 8 (one day prior to treatment) 760 
and approximately day 30 (21 days after treatment initiation) in (C) MIA PaCa-2 and (G) 761 
AsPC-1 orthotopic xenograft models. Approximately, a 90% reduction in mean tumor 762 
volume was observed in mice treated with ‘nal-IRI’ and ‘PDP+nal-IRI’ compared to the 763 
‘no-treatment’ control animals. Asterisks denote significance compared with no-764 
treatment group or amongst the indicated groups at each time point. (*P<0.05, **P<0.01, 765 
***P<0.001, n.s., non-significant, Kruskal–Wallis one-way ANOVA with Dunn’s post 766 
hoc test) The specific growth rate (SGR) of tumors during the treatment period (D, H) 767 
and post-treatment period (E, I) were determined using the following formula: SGR = 768 
(1/V)(dV/dt), where V is tumor volume and t is time. In the MIA PaCa-2 mouse model, 769 
shortly following the termination of treatment and up to 120 days, nal-IRI-treated animals 770 
experienced a rapid tumor regrowth at a significantly higher SGR (4.80.3 %/d), 771 
compared to the ‘no-treatment’ control tumors. In contrast, the combination of PDP and 772 
nal-IRI continued to suppress tumor growth to a low SGR (1.70.9 %/d) for a prolonged 773 
period of time up to 120 days. (*P<0.05, **P<0.01, ***P<0.001, n.s., non-significant, 774 
Kruskal–Wallis one-way ANOVA with Dunn’s post hoc test). (n = 9-13 mice per group 775 
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for MIA PaCa-2 model; n = 5-7 for AsPC-1 model). Results are mean ± standard error of 776 
the mean (SEM). 777 
Fig.4. PDP suppresses chemotherapy-induced enrichment of CD44
 
and CXCR4 expression in 778 
PDAC tumors. (A) Representative immunofluorescence images of CD44 and CXCR4 in 779 
MIA PaCa-2 tumors subjected to (1) no-treatment; (2) PDP (nal-BPD 0.25 mg/kg; 690 780 
nm light at 100 mW/cm
2
 to achieve 75 J/cm
2
); (3) four cycles of nal-IRI (nal-IRI; at 20 781 
mg/kg each, on days 9, 12, 17 and 21); and (4) PDP+nal-IRI. Significant increases in 782 
CD44 and CXCR4 expression were observed in tumors treated with nal-IRI alone at days 783 
60 and 120 post-implantation; Blue: DAPI (nuclei), Red: CD44, Green: CXCR4. Scale 784 
bar, 100 μm. (B, C) To quantify immunofluorescence intensities, at least 25 images, 785 
evenly distributed across the entire tumor cross-section, were collected from at least three 786 
tumor samples for each condition. CD44 and CXCR4 fluorescence intensities were 787 
normalized to DAPI area per image. Relative CD44 and CXCR4 levels were found to be 788 
significantly higher in the ‘nal-IRI’ groups compared to other groups. (*P<0.05, 789 
**P<0.01, ***P<0.001, Kruskal–Wallis one-way ANOVA with Dunn’s post hoc test) 790 
Asterisks denote significance compared to the no-treatment group or amongst the 791 
indicated groups at each time point. (D, E) Representative immunoblotting of CD44 and 792 
CXCR4 in tumors collected at day 120 confirmed that the enhanced protein expression of 793 
CD44 and CXCR4 after nal-IRI treatment could be effectively mitigated by PDP. (F) 794 
Representative CD44/CXCR4 double-stained images of MIA PaCa-2 tumors subjected to 795 
(1) no-treatment; (2) PDP (nal-BPD 0.25 mg/kg; 690 nm light at 100 mW/cm
2
 to achieve 796 
75 J/cm
2
); (3) four cycles of nal-IRI (nal-IRI; at 20 mg/kg each, on days 9, 12, 17 and 797 
21); and (4) PDP+nal-IRI. (G) The CD44+, CXCR4+, and CD44+/CXCR4+ areas of 798 
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tumors (collected at day 120) were quantified and normalized to DAPI area using ImageJ 799 
software. At least 12 images, evenly distributed across the entire tumor cross-section, 800 
were collected from at least four tumor samples for each condition. (*P<0.05, **P<0.01, 801 
***P<0.001, Kruskal–Wallis one-way ANOVA with Dunn’s post hoc test) Asterisks 802 
denote significance compared to the no-treatment group or amongst the indicated groups 803 
at each time point. (H) Immunoblot analysis of E-cadherin in MIA PaCa-2 primary tumor 804 
tissues at days 60 and 120. Expression of E-cadherin (relative to ‘PDP+nal-IRI’ at day 805 
120) was normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (n = 2-3; 806 
*P<0.05, **P<0.01, ***P<0.001, One-way ANOVA with Tukey’s post hoc test). (I) 807 
Representative Immunoblotting showed that the no-treatment, PDP, nal-IRI and treated 808 
tumors exhibited a complete loss of E-Cadherin expression, suggesting that ‘PDP+nal-809 
IRI’ may help reduce the dedifferentiation of cancer cells. Results in B, C, D, E and I are 810 
mean ± standard error of the mean (SEM). 811 
Fig.5. PDP enhances the anti-metastatic effects of multi-cycle nal-IRI in vivo. (A) To assess the 812 
efficacy of PDP and nal-IRI in controlling metastases, treatments were initiated nine days 813 
after MIA PaCa-2 tumor implantation in mice randomized to the following groups: (i) 814 
no-treatment; (ii) PDP (nal-BPD 0.25 mg/kg; 690 nm light at 100 mW/cm
2
 to achieve 75 815 
J/cm
2
); (iii) nal-IRI (four doses at 20 mg/kg each, on days 9, 12, 17 and 21); and (iv) 816 
PDP+nal-IRI. (B-D) The number of metastases to the liver, retroperitoneal lymph nodes, 817 
diaphragm and lung were quantified by qRT-PCR (see Methods) on day 60 and day 120 818 
after tumor implantation. (n > 11 per group; *P<0.05, **P<0.01, ***P<0.001, Kruskal–819 
Wallis one-way ANOVA with Dunn’s post hoc test). Asterisks denote significance 820 
compared with no-treatment group or amongst the indicated groups at each time point. 821 
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(B, C) The overall metastatic burden includes liver, lung, retroperitoneal lymph nodes, 822 
and diaphragm metastases. (D) Metastases to individual organs are presented. At day 60, 823 
both ‘nal-IRI’ and ‘PDP+nal-IRI’ completely inhibited liver metastasis and significantly 824 
reduced distant organ metastases to less than 50 cancer cells, as compared to the ‘no-825 
treatment’ group (>1 million cancer cells at lung, diaphragm, lymph node). At day 120, 826 
the combination treatment of PDP and nal-IRI significantly reduced liver and distant 827 
organ metastases by ~16,000-fold and ~40,000-fold (P<0.001), respectively, compared to 828 
the ‘no-treatment’ control. (E) The incidence of metastases in mice bearing orthotopic 829 
MIA PaCa-2 tumors were significantly reduced by the combination treatment on days 60 830 
and 120 (n > 11 per group). At day 120, the combination of PDP and nal-IRI effectively 831 
reduced the incidence of metastases to a range from 6.7 to 33.3%, while the incidence of 832 
metastases ranged from 60 to 100% in the ‘no-treatment’, ‘PDP’, and ‘nal-IRI’ groups. 833 
Fig.6. PDP and multi-cycle nal-IRI achieve durable and significant survival enhancement and 834 
reduce endpoint disease burden in two orthotopic PDAC models. (A) Swiss nude mice 835 
were orthotopically inoculated with MIA PaCa-2 or AsPC-1 cells, divided into four 836 
groups, and subjected to (1) no-treatment; (2) PDP (day 9 post-implantation; nal-BPD 837 
0.25 mg/kg; 690 nm light at 100 mW/cm
2
 to achieve 75 J/cm
2
); (3) multiple cycles of 838 
nal-IRI (nal-IRI; four doses at 20 mg/kg each, on days 9, 12, 17 and 21 post-839 
implantation); and (4) PDP+nal-IRI.  Moribundity was used as the endpoint for the 840 
survival study with proper justification and special approval by the MGH IACUC. 841 
Animals were monitored for up to 450 days (15 months). (B, C) Kaplan-Meier plot of 842 
overall animal survival (B) and progression-free survival (C) in MIA PACa-2 model. (n 843 
= 9-13 animals per group). (D) Kaplan-Meier plot of animal overall survival in the 844 
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AsPC-1 model. (n = 4-7 animals per group). (E) Median survival time, hazard ratio forest 845 
plot, and differences in survival were evaluated by the log-rank test. A global test 846 
demonstrated a difference exists among the groups. Specifically, pairwise comparisons 847 
were performed to evaluate the advantage of treatment over no-treatment. Animals 848 
treated with PDP+nal-IRI were found to be significantly less likely to die by the next 849 
time point (hazard ratio < 1). No advantage to monotherapies (compared to no-treatment) 850 
were observed. Primary tumor weight, metastatic burden, and ascites volume were 851 
evaluated at animal death or day 450. (F) The combination of PDP+nal-IRI 852 
significantly reduced the endpoint primary tumor weight by half compared to the 853 
monotherapies and the no-treatment group. (n = 3-5 animals per group, *P<0.05, 854 
Unpaired t test). (G) The ascites formation in moribund animals were significantly 855 
reduced after ‘nal-IRI’ and ‘PDP+nal-IRI’ treatments, compared to the ‘no-treatment’ 856 
arm. (n = 3-6 animals per group; (*P<0.05, **P<0.01, Unpaired t test). Asterisks denote 857 
significance compared with no-treatment group or amongst the indicated groups at each 858 
time point. Results are mean ± standard error of the mean (SEM). 859 
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